Pharvaris stock awaits pivotal HAE therapy data as BofA reiterates Underperform

Pharvaris B.V. (PHVS) has updated timelines for its deucrictibant hereditary angioedema (HAE) therapy, with pivotal Phase 3 data now expected in Q4 2025 and a potential NDA submission in H1 2026. This development highlights a strategic divergence among analysts: BofA Securities maintains an Underperform rating and $14 price target, citing competitive concerns given Kalvista's recent market entry and deucrictibant's delayed timeline. Conversely, JMP Securities reiterates a Market Outperform rating with a $55 price target, projecting significant peak sales and U.S. launches by 2027-2028 based on positive prior study data. Despite a strong cash position, the company is burning cash rapidly, making the forthcoming Q4 2025 data critical for its competitive positioning and future valuation.

Analysis

Pharvaris B.V. (PHVS) presents a polarized investment case following an updated timeline for its hereditary angioedema (HAE) therapy, deucrictibant. The company now expects pivotal Phase 3 data in Q4 2025, with a potential New Drug Application in H1 2026, pushing potential commercialization to 2027 or later. This delay sharpens the divide between analyst outlooks, exemplified by BofA Securities' 'Underperform' rating ($14 target) and JMP Securities' 'Market Outperform' rating ($55 target). BofA's caution is rooted in the competitive landscape, where Kalvista’s Ekterly has secured approval and at least a 12-month market head start, setting a high bar for deucrictibant's differentiation. In contrast, JMP's bullish thesis is supported by strong prior clinical data demonstrating rapid symptom relief and quality of life improvements, projecting peak sales over $2 billion across acute and prophylactic uses. Financially, Pharvaris possesses a strong balance sheet with significantly more cash than debt and a current ratio of 11.1, but this is offset by a rapid cash burn rate, heightening the execution risk associated with the extended clinical timeline. The wide dispersion of analyst price targets ($14.73 to $56.46) accurately reflects this high degree of uncertainty and the binary nature of the upcoming trial results.

Key Decisions for Investors

• Investors should view Pharvaris as a high-risk, high-reward biotechnology play, with valuation heavily dependent on the binary outcome of the RAPIDe-3 trial data expected in Q4 2025.
• Monitor the company's quarterly cash burn rate closely, as the extended timeline to potential revenue in 2027 increases financial risk despite a currently strong balance sheet.
• Track the market penetration and initial sales of Kalvista's competing drug, Ekterly, as its performance will serve as a critical benchmark for deucrictibant's potential market share and commercial viability.
• The significant divergence between BofA's bearish $14 target and JMP's bullish $55 target underscores the central debate; positions should align with an investor's conviction regarding deucrictibant's ability to clinically differentiate itself from an established competitor.